AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05225012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Participants will then commence the intervention for the next 4 weeks. They will be sent the workbook via post. This will not be a standalone self-help intervention; participants will progress through the workbook alongside weekly emotional support sessions. These will either be over the phone or using an online video-call software, depending on participants preference. The first session will be an hour long to set-up the workbook, answer questions and go through goal setting. The following three weekly sessions will be half an hour to revisit exercises in the workbook, answer questions and review how the workbook progress is going. All sessions will be delivered by a trainee clinical psychologist who will receive standardised training and ongoing supervision from an experienced clinical psychologist.
Study NCT05909709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alocyte low dose
Description: Low dose containing 0.2 - 1.0 x 10\^11 particles and 3-10x10\^6 cell in 2mL which will be administered intra-facet into a single facet joint.~Preparation of low dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 2ml of the diluted product will be used.
Study NCT05909709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alocyte medium dose
Description: Medium dose containing 0.6 - 3.0 x 10\^11 particles and 9-30x10\^6 cell in 6mL which will be administered intra-facet into three facet joints delivering 2ml/facet joint.~Preparation of medium dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 6ml of the diluted product will be used.
Study NCT05909709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alocyte high dose
Description: High dose containing 1.0 - 5.0 x 10\^11 particles and 15-50x10\^6 cell in 10mL which will be administered intra-facet into five facet joints delivering 2ml/facet joint.~Preparation of high dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, 10ml of diluted product will be used.
Study NCT05267444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized motion-based interactive game program
Description: The participants will receive a 12-session, 4.5 months home visit service that is provided by the young adults, and supervised by an occupational therapist. Young adults will follow the individualized exercise plan with the older adults, facilitate their use of interactive games, provide psychological and technological support to help older adults cope with their fear of using technologies to perform physical activity.
Study NCT06411392 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Antiarrhythmic Radiotherapy
Description: Patients with ventricular tachycardia will undergo cardiac stereotactic antiarrhythmic radiotherapy with a single fraction of 25 Gy to the arrhythmia substrate, as determined by electrophysiological cardiac mapping.
Study NCT04880356 — intervention group
Intervention type: OTHER
Intervention: collection of data
Description: collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases
Study NCT06468969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Follow-up
Description: Participants will receive comprehensive follow-up care starting from the 4th week post-surgery. Every 3 weeks, they will undergo a thorough assessment that includes:~Symptom Assessment Nutritional Assessment (using NRS 2002 and PG-SGA) Psychological Assessment (using DT, GAD-7, FCR-7, ISI, PHQ-9)
Study NCT06468969 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Follow-up
Description: Participants will receive comprehensive follow-up care starting from the 4th week post-surgery. Every 3 weeks, they will undergo a thorough assessment that includes:~Symptom Assessment Nutritional Assessment (using NRS 2002 and PG-SGA) Psychological Assessment (using DT, GAD-7, FCR-7, ISI, PHQ-9)
Study NCT06423417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeHack
Description: See arm description
Study NCT04914507 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Anterior Vertebral Body Tethering
Description: Subject will receive anterior vertebral body tethering surgery.
Study NCT04985370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Three sessions of pain neuroscience education based on explaining patients: characteristics of acute versus chronic pain, function of acute pain, how acute pain is originated within the nervous system, how acute pain progress to chronic pain, and factors that contribute to central sensitization (e.g., emotions, stress, disease and pain beliefs, behaviors regarding pain...). All the explanations will be conducted using easy-understandable examples and metaphors.
Study NCT04985370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Progressive resistance exercise program based on isometric, concentric, eccentric, and pliometric contractions.
Study NCT04985370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Progressive resistance exercise program based on isometric, concentric, eccentric, and pliometric contractions.
Study NCT04073329 — intervention group
Intervention type: OTHER
Intervention: post operative measure of reduction
Description: measurement was used to grade quality of reduction according to Matta's system . In accordance with prior studies, adequate (or anatomic) reductions with 0-1 mm of displacement were compared to inadequate (imperfect or poor) reductions with > 1 mm displacement . For the CT-based method, postoperative pre-digital (prior to 2000) and digital CT images were independently assessed in the axial, sagittal, and coronal planes, and residual gap and step displacement were measured along the articular surface at the level of the weight-bearing dome. Adequate reductions on postoperative CT were defined as \< 1 mm step and \< 5 mm gap displacement and inadequate reductions as ≥ 1 mm step and/or ≥ 5 mm gap displacement.
Study NCT05437250 — intervention group
Intervention type: DRUG
Intervention: Non interventional study
Description: CLL patients initiated with acalabrutinib at their physician's discretion between January 1, 2021 and December 31, 2022 . Secondary data collection
Study NCT06116643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble protein hydrolysate (SPHi)
Description: Participants that are already on stable maintenance therapy for ulcerative colitis will continue with their therapy regimen and the addition of 10g of SPHi in 100ml of water every day for 12 weeks.
Study NCT04121208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-40346527
Description: Active study drug
Study NCT04121208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active study drug
Study NCT05925881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Repair of Large to Massive Rotator Cuff Tears
Description: Surgical procedure to reconstruct the rotator cuff
Study NCT06464510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Vasopressin
Description: Early Vasopressin group: Vasopressin up to 0.04U/min initiated after randomization.
Study NCT06464510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine and Vasopressin for Rescue
Description: Norepinephrine and Vasopressin for Rescue group: Vasopressin up to 0.04U/min initiated only if norepinephrine dose exceeds 0.5 μg/kg/min.
Study NCT05091489 — intervention group
Intervention type: OTHER
Intervention: Qualitative assessment about PrEP acceptability
Description: Qualitative research among key-populations, community and healthcare workers, and decision and policy makers, including focus group and semi-directive interviews
Study NCT06439719 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample collection
Description: Collection of blood sample
Study NCT05341453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Individual physiotherapy (SMA-SOC)
Description: Therapeutic procedures according to the recommended standard (SMA-SOC) will be used in the therapy. Elements of breathing gymnastics, vibration techniques, stretching, eccentric and concentric exercise procedures will be combined. Individual physiotherapy will be conducted on the basis of set goals from the kinesiological examination, it will be adapted to the individuality of the child - his cooperation, fatigue and sleep time.
Study NCT05341453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: HT by CP is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators anticipate it´s effect for children with SMA.~Based on a special type of examination, this method precisely determines the type / breed of the horse according to the biomechanics of the movement of its back in the step, the position of the child and the neurophysiological function of the back - differentiation or sensorimotor skills. Furthermore, according to the course of therapy, the physiotherapist determines the pace of the horse's step, its length, selects special manual contacts according to the current situation and adjusts the duration of therapy to the client's fatigue.~Therapy will be performed by therapists with professional competence to perform hippotherapy by children with CP.
Study NCT05341453 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Therapeutic grooming
Description: In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA. The purpose of this activity is to clean the horse, its possible guide, stroking and contact with the horse, work from the ground.
Study NCT06505005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT) Other Names:
Description: Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT)
Study NCT06505005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Patch without haptic vibrotactile trigger technology (VTT)
Description: Sham Patch without haptic vibrotactile trigger technology (VTT)
Study NCT06505005 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Patch without haptic vibrotactile trigger technology (VTT)
Description: Sham Patch without haptic vibrotactile trigger technology (VTT)
Study NCT06339437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS Protocol
Description: Ehanced recovery after surgery protocols were applied
Study NCT05469685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker
Study NCT05469685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker
Study NCT05469685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT05469685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT06523153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VYD2311
Description: Monoclonal antibody
Study NCT06523153 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT04980573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: The aromatherapy intervention consists of inhaling a fragrant oil extracted from citrus peels, plant resins, and leaves.
Study NCT04980573 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo intervention consists of inhaling an oil extracted from inert plant matter.
Study NCT05572229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered via a subcutaneous injection (SC)
Study NCT05572229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered via a subcutaneous injection (SC)
Study NCT05572229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally
Study NCT05240950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CEA CAR-T Cells
Description: The study will evaluate the safety of intravenous infusion of anti-CEA CAR-T (+) cells in humans at doses of 1×10\^6/kg, 3×10\^6/kg, and 6×10\^6/kg using a standard 3+3 design and preliminarily observe the efficacy.
Study NCT05321160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: 0.25 mg/kg esketamine for induction and 0.25 mg/kg esketamine at the beginning of surgery
Study NCT05321160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 4% sevoflurane for induction and 2-4% sevoflurane for maintain
Study NCT05697744 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vidiac Score
Description: Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
Study NCT06404424 — intervention group
Intervention type: DEVICE
Intervention: Efferon LPS
Description: Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of sepsis to improve hemodynamic function and abrogate septic shock.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption
Study NCT06404424 — intervention group
Intervention type: DEVICE
Intervention: Efferon CT
Description: Efferon CT, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that adsorbs excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of cytokine storm syndrome in the course of severe SARS-CoV-2.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption
Study NCT05596396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeHack
Description: Participants assigned to LifeHack will follow a six week-guided online intervention with a fixed structure where the themes are delivered in a predefined order, and the contents get unlocked sequentially. The first mandatory module is the introduction module which also functions as a goal-setting module. Following this, students complete one mandatory module per week (and the optional modules if they choose to do so) delivered sequentially, starting with the theme of mood, studies, social life and finally, self-esteem. Students complete the themes one by one and the consecutive themes (and modules) are unlocked only after completing the main module of the assigned theme.
Study NCT05596396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LifeHack-C
Description: Participants assigned to LifeHack-C will receive the same guided online intervention, but they can choose what theme they would like to start with, when to work on it and how many modules they wish to complete. After completing the introduction module, the participants will be advised to complete two modules per week and at least four in total. Therefore, the program's duration will be approximately two and six weeks. However, participants can follow the program at their own pace.
Study NCT04807140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab, nab-paclitaxel, carboplatin
Description: Patients receive Toripalimab IV on day 1, nab-paclitaxel IV on day 1 and carboplatin IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT04807140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Patients receive Toripalimab IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT04807140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical therapy will be at the discretion of the treating surgeon per standard of care.
Study NCT05091502 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Personalised musculoskeletal modeling
Description: Magnetic resonance images, electromyography and dynamometry data will be used to develop personalised musculoskeletal models
Study NCT06110520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Violet Light Lamp
Description: Medical grade lamps with Violet LEDs enabled
Study NCT06110520 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: White Light Lamp
Description: Standard bedside lamp with standard 4000K LED light bulb.
Study NCT06494423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work Support (WorkS)
Description: The WorkS intervention entails two structured visits with a research team member initiated 6-months post-HSCT, which is the earliest point at which most HSCT survivors can safely consider returning to work. The sessions are focused on 1) identifying challenges of navigating work and illness; 2) linking survivors with psychological, rehabilitative, governmental, and community resources that can promote recovery and well-being; and 3) communicating with employers regarding the necessary work modifications to achieve mutual goals.
Study NCT04231110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Use of fecal microbiota transplantation enemas once weekly in patients who are initiating vedolizumab treatment
Study NCT06084429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre and post test (health educational intervention)
Description: The health education will be provided the following sessions.~Introduction to Global and Bangladesh Health, Health Information access (Validity), Critical Values (Vital signs, BMI, RBS etc.), Emergency Management (burn, chocking, knife cut, fainting etc.), Food (classification, healthy food, unhealthy, food label, salt intake) (NCDs from unhealthy diet), Smoking and Alcohol (NCD related, substance abuse, secondhand smoking), Physical activity (Benefits, sedentary lifestyle, NCD related), Women's health (menstruation, menstrual cycle, hygiene, STD, contraception), Hygiene (water, food, brushing, bath, toileting, healthy habits), Environmental Sanitation and Communicable disease (clean, effects on health), and Women's health and societal contribution
Study NCT05861284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation method that can induce long-term changes in connections between neuronal networks.
Study NCT05861284 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation method that can induce long-term changes in connections between neuronal networks.
Study NCT05118087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Webril Padded Plaster Splint
Description: Patients in the coaptation splint group will have a webril padded plaster splint that is placed around the humerus. The forearm and wrist are then suspended in a cuff and collar.
Study NCT05118087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Fabricated Fracture Brace
Description: Patients in the sarmiento group will be given a fitted pre-fabricated fracture brace with a cuff and collar for the forearm. The patients will be educated on brace maintained, tightening, and care during at the time of the ER encounter.
Study NCT05282342 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic tests
Description: No intervention will be carried out. Participants of the whole groups will be underwent the same tests.
Study NCT06410911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal Transversus Abdominis Plane block in patients undergoing open cholecystectomy surgery.
Description: Subcostal Transversus Abdominis Plain block will be performed under ultrasound guidance using a 5-10 MHz linear transducer. The needle will be inserted perpendicular to the skin 2 fingers below the costal~margin, just lateral to the rectus abdominis muscle. After confirming the needle tip's location within the TAP, 20 mL of 0.25% bupivacaine will be injected on both sides in patients undergoing open cholicystectomy surgery.